심장 약물 안전 검사를위한 인간 공학 심장 조직의 자동 수축 분석

Executive Industry Relevance

Automated contraction analysis of human engineered heart tissue provides a scalable, standardized platform for early cardiac drug safety screening, enabling quantitative assessment of contractile force and drug-induced arrhythmia risk. This approach supports mechanistic de-risking by replicating human cardiac responses to pharmacological agents like hERG inhibitors, improving target validation confidence. The method enhances predictive value in lead identification by bridging stem cell-derived models with functional readouts relevant to clinical safety outcomes.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through force-generating human heart tissue models that reflect disease-relevant contractile physiology.
• Operational Value: Supports biological de-risking by detecting drug effects on contraction kinetics and relaxation times in a human-derived system.
• Predictive Value: Generates quantitative data on T2 prolongation and beating irregularity to prioritize targets with improved cardiac safety profiles.

Screening & Assay Development

• Assay Readiness: Produces standardized, sterile 3D tissues in 24-well format compatible with automated imaging and contraction analysis workflows.
• Quantitative Output: Measures shortening-based force via PDMS post deflection, enabling dose-response assessment of compounds like E-4031.
• Scalability: Allows generation of several hundred engineered heart tissues per week, limited only by cardiomyocyte availability, supporting medium-throughput screening.

Translational & Preclinical Research

• Disease Relevance: Uses human cardiomyocytes to model contraction dynamics, improving translational alignment with human cardiac function.
• Mechanistic Continuity: Captures auxotonic contractions and relaxation parameters that reflect electromechanical coupling, supporting preclinical risk assessment.
• Decision Support: Enables replication of drug-induced contractile changes, informing go/no-go decisions in lead optimization.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead identification to preclinical safety assessment, providing functional validation of molecular targets in a human tissue context.

• Discovery Biology: Facilitates hypothesis testing on gene variants and drug effects by measuring real-time contractile force in engineered human heart tissue.
• Screening: Delivers reproducible, automated contraction readouts that support assay standardization and compound screening under controlled conditions.
• Analytics: Generates quantifiable parameters including contraction amplitude, beating frequency, and T2 relaxation time for comparative analysis across conditions.
• Translational Research: Uses human-derived tissues to bridge in vitro findings with clinical safety expectations, particularly for ion channel liabilities.
• Enterprise Reuse: Establishes a reusable platform for cardiac safety screening that can be applied across multiple projects and target classes.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity in cardiac drug response.
• Operational Value: Ensures reproducibility and standardization through automated figure recognition and controlled environmental conditions.
• Strategic Value: Improves capital efficiency by identifying cardiotoxic compounds early, reducing late-stage attrition risk.
• Portfolio Impact: Supports risk-adjusted advancement decisions through quantitative safety signals derived from human heart tissue models.

Implementation Considerations

• Requires expertise in cardiac tissue engineering, sterile cell culture, and cardiomyocyte handling.
• Depends on imaging hardware with XYZ axis control and automated figure recognition software for contraction detection.
• Necessitates cross-team standardization of tissue generation, drug exposure, and analysis protocols for reproducible results.
• Involves adaptation considerations when extending to different cell sources or genetic models while maintaining tissue integrity and function.
• Limited by cardiomyocyte availability and maturation state, which affects contractile performance and assay consistency.

Biopharma FAQs